BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28836284)

  • 1. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Shi CR; Nambudiri VE
    Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
    Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
    Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 6. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Horizontal melanonychia.
    Salman A; Eser A; Kaygusuz Atagunduz I; Ergun T
    Actas Dermosifiliogr; 2017 Jun; 108(5):469-470. PubMed ID: 27543192
    [No Abstract]   [Full Text] [Related]  

  • 9. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
    Scott AD; Lee M; Kubba F; Chu A
    Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib-induced pseudoporphyria.
    Martinez-Mera C; Capusan TM; Herrero-Moyano M; Urquía Renke A; Steegmann Olmedillas JL; de Argila D
    Clin Exp Dermatol; 2018 Jun; 43(4):463-466. PubMed ID: 29315788
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
    Eşkazan AE
    Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
    McGrath K; Stein B; Kalhagen L; Leighton L
    Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
    [No Abstract]   [Full Text] [Related]  

  • 15. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 16. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
    Schwarz M; Kreuzer KA; Baskaynak G; Dörken B; le Coutre P
    Eur J Haematol; 2002 Oct; 69(4):254-6. PubMed ID: 12431246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
    Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
    J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
    [No Abstract]   [Full Text] [Related]  

  • 19. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
    Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
    An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Eskazan AE; Tiribelli M
    Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.